ERBB2 and malignant colon neoplasm: The first evidence on the clinical use of HER2-CAR-T cells was a case report of a patient with metastatic HER2+ colon cancer in whom the administration of a 3rd generation HER2-CAR was followed by multiple cardiac arrests, respiratory distress, and multiorgan damage (62).